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Introduction 
In December 2014, Ana Liffey Drug Project launched ‘Targeting Harm’1, its strategic plan for 
the period 2015 - 2017. One of the overarching strategic objectives is “We will innovate to 
ensure we meet the needs of our Service Users through progressive initiatives”. One of the 
goals under this objective commits the organization to: 
“Secure stakeholder support, plan and pilot the provision of Medically Supervised 
Injecting Centres” 
 
This paper sets out the position of ALDP with regard to MSICs2. Our hope is that it provides 
an accessible foundation for discussion and engagement with all stakeholders.  
What is an MSIC? 
An MSIC is a type of Drug Consumption Room (DCR). DCRs seek to reduce the harm 
associated with drug use by allowing certain types of drug consumption on the premises. 
MSICs focus on injecting drug use. They are medically supervised spaces where people can 
inject drugs in a clean and hygienic setting off the street. They are a widely recognised 
response to injecting drug use, and are employed in a number of countries, including 
Switzerland, Germany, Spain, the Netherlands, Australia and Canada 3 . France has also 
recently voted to introduce DCRs4.  An MSIC does not provide people with drugs to consume; 
people arrive at the MSIC with their drug. At the MSIC, they can access clean injecting 
equipment, and medical and social interventions, such as testing for blood borne viruses, 
advice on safer drug use, and referral pathways to treatment and rehabilitation. 
What are the benefits of MSICs? 
MSICs have been shown to improve both health related indicators for drug users and broader 
environmental indicators such as the reduction of unsafely discarded paraphernalia. The 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a decentralised 
                                                     
1 http://www.aldp.ie/resources/ALDP_strategic_plan_2015-2017.pdf 
2 This document is an updated version of a position paper first published in April 2012. The original version of the 
position paper is available online at 
http://www.aldp.ie/resources/Ana_Liffey_MSIC_Position_Paper_April_2012_Final.pdf 
3 Hedrich, D. (2004). European report on drug consumption rooms. Luxembourg, Office for Official Publications of the 
European Communities. 
4 http://idhdp.com/en/resources/news/april-2015/france-passes-bill-allowing-drug-consumption-rooms.aspx 
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agency of the EU. It exists to provide the EU and its Member States with a factual overview of 
European drug problems and a solid evidence base to support informed drug laws and 
strategies. In its European Drug Report 2015, the EMCDDA noted the following in relation to 
DCRs: 
“… the benefits of providing supervised drug consumption facilities may include 
improvements in safe, hygienic drug use, especially among regular clients, 
increased access to health and social services, and reduced public drug use 
and associated nuisance. There is no evidence to suggest that the availability 
of safer injecting facilities increases drug use or frequency of injecting. These 
services facilitate rather than delay treatment entry and do not result in higher 
rates of local drug-related crime.” 5 
 
Similarly, a report commissioned by the Joseph Rowntree Foundation in 2006 found that there 
is no evidence that DCRs either increase or decrease an individual’s drug use, or that they act 
as a magnet for drug users. However, DCRs were associated with a reduction in injecting in 
public places, and a reduction in discarded used syringes and drug-related litter6. For example, 
in Barcelona a fourfold reduction was reported in the number of unsafely disposed syringes 
being collected in the vicinity from a monthly average of over 13,000 in 2004 to around 3,000 
in 20127. Other positive findings include evidence that DCRs can be a successful gateway to 
treatment8 and can reduce ambulance call-outs for drug overdoses9. 
It is important that MSICs are provided not as standalone services, but as a response that is 
integrated into current service provision. EMCDDA notes that: 
 “In settings where there is a demonstrable need for DCRs, their development 
and the extent to which they can achieve their objectives is tempered by the 
                                                     
5 European Monitoring Centre for Drugs and Drug Addiction (2015). “Drug consumption rooms: an overview of 
provision and evidence”. Available online at: http://www.emcdda.europa.eu/topics/pods/drug-consumption-
rooms#ref23Online 
6 Joseph Rowntree Foundation (2006). The Report of the Independent Working Group on Drug Consumption. York. 
7 Vecino, C., Villalbí, J. R., Guitart, A., et al. (2013), Safe injection rooms and police crackdowns in areas with heavy drug 
dealing: evaluation by counting discarded syringes collected from the public space (in Spanish), Addiciones 25(4), pp. 333–
8. 
8 Kimber, J., R. P. Mattick, et al. (2008). “Process and predictors of drug treatment referral and referral uptake at the Sydney 
Medically Supervised Injecting Centre.” Drug and Alcohol Review 27(6): 602-612. 
9 Salmon, A. M., I. Van Beek, et al. (2010). “The impact of a supervised injecting facility on ambulance call-outs in Sydney, 
Australia.” Addiction 105(4): 676-683. 
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broader social and policy context. A qualitative assessment of the literature 
suggests that DCRs can only be effective if they are: 
- integrated into a wider public policy framework as part of a network of 
services aiming to reduce individual and social harms arising from 
problem drug use; 
- based on consensus, support and active cooperation among key local 
actors, especially health, police, local authorities, local communities and 
consumers themselves;  
- seen for what they are — specific services aiming to reduce problems 
of health and social harm involving particular high-risk populations of 
problematic drug users and addressing needs that other responses 
have failed to meet.”10 
 
Why do we need MSICs in Dublin? 
Drug use in Dublin’s public spaces is a matter of significant concern to the general public. In 
2005, the Lord Mayor’s Commission on Crime and Policing highlighted public perception of 
the problem of public injecting in Dublin: 
“…addicts injecting in public places…a sight [which] causes distress to 
members of the public who feel threatened by such overt drug abuse on the 
streets…and a perception of lawlessness often ensues”11  
 
Local stakeholders have consistently identified public drug use as a problem, with:  
“… over one in three respondents (36% of respondents) describing antisocial 
behavior (particularly drink and drug related behavior, crime and safety issues) 
as being the worst thing about Dublin. There were over 400 mentions of drugs 
and drug use in the open responses. Many of the panel members feel that this 
                                                     
10  European Monitoring Centre for Drugs and Drug Addiction (2010). “Harm reduction: evidence, impacts and 
challenges.” EMCDDA Scientific Monograph 10. 
11 Lord Mayor’s Commission (2005). The Lord Mayor’s Commission on Crime and Policing. Dublin, The Lord Mayor’s 
Office, Mansion House, Dublin 2: 45 
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has had a serious impact on the image of the city centre and is something that 
needs urgent attention from all stakeholders that operate in the city.”12 
 
This general public sentiment is backed up with objective research with drug users. A 2005 
study showed that 68% of 66 homeless intravenous drug users (IDUs) reported injecting in a 
public place in the past month13. A client survey carried out by Ana Liffey Drug Project in 2008 
found that of the 16 respondents who reported where they had injected 30 days prior to 
interview, 9 (56%) reported using in public places14. More recently, Merchants Quay Ireland 
reported that 44 (14%) people who used the needle exchange service generally injected in 
public places15. 
Public injecting is not only a concern to the general public, but also to the individual drug user. 
Long notes that at the end of 2009 there were 5,369 diagnosed HIV cases in Ireland, of which 
1,447 (27%) were probably infected through injecting drug use; further, in 2009, 40% of newly 
reported hepatitis C cases had risk factor status recorded16. The majority of these cases 
(70.9%) reported injecting drug use as the main risk factor. The spread of blood borne viruses 
among injecting drug users occurs in part through unsafe injecting behaviours. A number of 
studies show elevated levels of risk behaviour among street injecting populations17. In early 
2015, there has been an increase in the number of new HIV cases diagnosed among people 
who inject drugs, and this increase may be related to injecting drug use among a public 
injecting cohort18.  
Given the impact of public injecting on health, the Irish Medical Organisation note that it is 
imperative that MSICs are considered in the Irish context: 
“Several other EU states, such as Portugal, Germany, and Spain have introduced 
such sites, which concentrate on harm reduction and prioritising the health interests 
                                                     
12  Cudden, J. (2011). “Your Dublin Your Voice” Top Line Results. Your Dublin Your Voice. Dublin, Office of 
International Relations and Research, Dublin City Council. 
13 Lawless, M., and Corr, C. (2005). Drug Use Among the Homeless Population in Ireland. Dublin, NACD. 
14 Keane, M. (2008). Ana Liffey Drug Project. Client Survey. Dublin, Ana Liffey Drug Project: 64. 
15 Jennings, C. (2014). Re-establishing Contact: A profile of clients attending the Health Promotion Unit – Needle 
Exchange at Merchants Quay Ireland. Dublin: Merchants Quay Ireland 
16 Long, J. (2011). Update on blood-borne viral infections in injecting drug users. Drugnet Ireland. Dublin, Health 
Research Board. Spring 2011 19-21. 
17 Marshall, B. D. L. K., T. Qi, T. Montaner, J. Wood, E. (2010). “Public injecting and HIV risk behaviour among street-
involved youth.” Drug and Alcohol Dependence 110: 254-258. 
18  See, for example, http://www.irishexaminer.com/ireland/hse-sets-up-intervention-team-over-rise-in-hiv-cases-
333521.html 
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of the drug user. International research has established the ability of such facilities to 
reduce drug-related harm to users, and so this option must be properly assessed as 
a potential viable public health measure to tackle drug-related harm.” 19 
Thus, public injecting creates risk for both the general public and the individual drug user. Ana 
Liffey Drug Project believes that MSICs would help take public injecting off the streets and 
provide a safer alternative that benefits all the city’s stakeholders. 
Isn’t allowing people to use drugs on your premises illegal? 
Yes. In order for MSICs to be able to operate legitimately in Ireland, it is necessary to make 
legislative changes. The Ana Liffey Drug Project has worked with the Voluntary Assistance 
Scheme of the Bar Council of Ireland to develop draft legislation which, if enacted, will create 
a legal framework within which MSICs can operate under licence. The organization is currently 
working with stakeholders to secure the passage of the legislation through the Oireachtas.  
 
Where would an MSIC be located? 
The Ana Liffey is willing to provide the service at a central location in Dublin City Centre, where 
public injecting is a well-established phenomenon, as is overdose 20 . However, the 
organisation’s current focus is on the establishment of a legal framework within which MSICs 
can operate under licence in Ireland. Once this has been achieved, it will be necessary to 
enter a suitable consultation process which provides an opportunity for all stakeholders to 
share their views prior to any service delivery commencing.  
 
How will the pilot service operate? 
Broadly, the service will operate three separate sections, consistent with MSIC design in other 
jurisdictions. Each section also has a number of distinct areas for specialist interventions. A 
reception area is used to greet, assess and register clients. The main section of the service is 
an injecting room, with spaces for individuals to inject in privacy, but with medical supervision 
and interventions available. A social section allows clients to avail of non-medical support and 
                                                     
19  IMO (2015) IMO Position Paper on Addiction and Dependency. Online at http://www.imo.ie/news-
media/publications/Addiction-and-Dependency-IMO-Position-Paper-(HR2).pdf; page 17 
20  On overdose, see, e.g., Klimas, Jan and O'Reilly, Martin and Egan, Mairead and Tobin, Helen and Bury, 
Gerard (2014) Urban overdose hotspots: a 12-month prospective study in Dublin ambulance services. The American 
Journal of Emergency Medicine, 32 (10). pp. 1168-1173 
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interventions before they exit the service. The service is staffed by a mix of medical and social 
care personnel, all specifically trained for work in an MSIC environment. 
What happens next? 
The Ana Liffey Drug Project is engaging with a variety of stakeholders around the passage of 
legislation through the Houses of the Oireachtas. This work is aided by the fact that we are 
not alone in our efforts – a number of leading NGOs are also in favour of the introduction of 
MSICs to Dublin, such as Merchant’s Quay Ireland and the Peter McVerry Trust21.   We also 
welcome queries from stakeholders in relation to MSICs. You can use the details below to 
contact us.  
 
Ana Liffey Drug Project 
48 Middle Abbey Street 
Dublin 1 
info@aldp.ie 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                     
21 See, for example http://www.thejournal.ie/overdose-injecting-centre-1645104-Aug2014/ 
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